Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: Can renal scintigraphy be safely omitted?

Nuclear Medicine Communications

Volumn 35, Issue 11, 2014, Pages 1143-1149

  Werner, Rudolf A ^a   Bluemel, Christina ^a   Lapa, Constantin ^a   Muegge, Dirk O ^b   Kudlich, Theodor ^a   Buck, Andreas K ^a   Herrmann, Ken ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Kidney function; Laboratory tests; Mercaptoacetyltriglycine; Neuroendocrine tumor; Peptide receptor radionuclide therapy

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; MERTIATIDE TC 99M; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE; RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DRUG CLEARANCE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MIDDLE AGED; PANCREATIC NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PREDICTIVE VALUE; RADIOISOTOPE THERAPY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; THYROID MEDULLARY CARCINOMA; UREA NITROGEN BLOOD LEVEL; VERY ELDERLY; ADVERSE EFFECTS; DIAGNOSTIC USE; KIDNEY; KIDNEY FUNCTION TEST; LABORATORY; METABOLISM; PATHOPHYSIOLOGY; RADIATION RESPONSE; RADIOTHERAPY; SAFETY; SCINTISCANNING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LABORATORIES; MALE; MIDDLE AGED; RADIOTHERAPY; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; SAFETY; TECHNETIUM TC 99M MERTIATIDE; YOUNG ADULT;

EID: 84916229979     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000194     Document Type: Article

References (32)

1. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40:800-816.
2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72.
3. Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012; 26:867-881.
4. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009; 50:936-941.
5. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptortargeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40:173-185, ix.
6. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010; 40:78-88.
7. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941-945.
8. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110-122.
9. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32:141-147.
10. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417-422.
11. Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2013; 54:1857-1861.
12. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29:2416-2423.
13. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46 (Suppl 1):83S-91S.
14. Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging 2014; 41:505-510.
15. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552-1554.
16. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487): a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30:510-518.
17. Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med 1986; 27:111-116.
18. Taylor A Jr, Eshima D, Fritzberg AR, Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med 1986; 27:795-803.
19. Hauser W, Atkins HL, Nelson KG, Richards P. Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. Radiology 1970; 94:679-684.
20. Halkar R, Taylor A, Manatunga A, Issa MM, Myrick SE, Grant S, Shenvi NV. Monitoring renal function: a prospective study comparing camera-based technetium-99m mercaptoacetyltriglycine clearance and creatinine clearance. Urology 2007; 69:426-430.
21. Hahn K, Pfluger T, Franzius C. DGN-practice guideline (S1-guideline): renal scintigraphy with and without furosemid in children and adults (register number 031-042). Available at: www.awmf.org/leitlinien/detail/ll/031-042.html. [Accessed 1 July 2014].
22. Esteves FP, Halkar RK, Issa MM, Grant S, Taylor A. Comparison of camerabased 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function. Am J Roentgenol 2006; 187:W316-W319.
23. Eshima D, Taylor A Jr. Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent. Semin Nucl Med 1992; 22:61-73.
24. Mustafa S, Alsughayer A, Elgazzar A, Elassar A, Al Sagheer F. Effect of sulfa drugs on kidney function and renal scintigraphy. Nephrology (Carlton) 2014; 19:210-216.
25. Russell CD, Dubovsky EV. Reproducibility of single-sample clearance of 99mTc-mercaptoacetyltriglycine and 131I-orthoiodohippurate. J Nucl Med 1999; 40:1122-1124.
26. Kuwert T, Grünwald F, Haberkorn U, Krause T. Nuclear medicine. Stuttgart: Thieme Verlag; 2007.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
29. Lew SW, Bosch JP. Effect of diet on creatinine clearance and excretion in young and elderly healthy subjects and in patients with renal disease. J Am Soc Nephrol 1991; 2:856-865.
30. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
31. Hood B, Attman PO, Ahlmén J, Jagenburg R. Renal hemodynamics and limitations of creatinine clearance in determining filtration rate in glomerular disease. Scand J Urol Nephrol 1971; 5:154-161.
32. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830-838.